Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8:a030361. https://doi.org/10.1101/cshperspect.a030361.

Article  PubMed  PubMed Central  Google Scholar 

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.

Article  CAS  PubMed  Google Scholar 

Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer. 2002;95:2302–7.

Article  PubMed  Google Scholar 

van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75:967–87.

Article  PubMed  Google Scholar 

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–39.

Article  CAS  PubMed  Google Scholar 

Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67:1009–16.

Article  PubMed  Google Scholar 

Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO Guideline Update. J Clin Oncol. 2021;10:1274–305.

Article  Google Scholar 

National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Available at www.NCCN.org. 2022.

Crawford ED, Harris RG, Slovin SF, Concepcion RS, Albala DM, Gomella LG, et al. Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII). JU Open Plus. 2023;1.

Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747–56.

Article  CAS  PubMed  Google Scholar 

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–28.

Article  PubMed  PubMed Central  Google Scholar 

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2021;205:14–21.

Article  PubMed  Google Scholar 

van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel recommendations. Eur Urol Focus. 2020;6:231–4.

Article  PubMed  Google Scholar 

Mottet N, Cornford P, van den Berg RCN, Briers E, Eberli D, De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. 2023. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf.

Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time. Am Soc Clin Oncol Educ Book. 2018;38:355–62.

Article  PubMed  Google Scholar 

Godoy G, Tareen BU, Lepor H. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Urology. 2009;74:167–70.

Article  PubMed  Google Scholar 

Makarewicz R, Lebioda A, Terlikiewicz J, Biedka M, Wiśniewski T. PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up. J Contemp Brachytherapy. 2009;1:92–96.

PubMed  PubMed Central  Google Scholar 

Szymaniak JA, Washington SL, Cowan JE, Cooperberg MR, Lonergan PE, Nguyen HG, et al. The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-022-00638-y.

Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365–9.

Article  PubMed  Google Scholar 

Chung JH, Jeong JY, Lee JY, Song W, Kang M, Sung HH, et al. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value. PLoS One. 2021;16:e0249709.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part i: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–90.

Article  PubMed  Google Scholar 

Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1963–96.

Article  CAS  PubMed  Google Scholar 

Wu S, Lin SX, Cornejo KM, Crotty RK, Blute ML, Dahl DM, et al. Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: a systematic review and meta-analysis. Asian J Urol. 2022;10:317–28.

Article  PubMed  PubMed Central  Google Scholar 

Wu X, LV D, Eftekhar M, Khan A, Cai C, Zhao Z, et al. A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients. Transl Androl Urol. 2020;9:2572–86.

Article  PubMed  PubMed Central  Google Scholar 

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012;110:1122–8.

Article  PubMed  PubMed Central  Google Scholar 

Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441–5.

Article  CAS  PubMed  Google Scholar 

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–71.

Article  PubMed  Google Scholar 

Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol. 2019;75:896–900.

Article  PubMed  Google Scholar 

Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013;8:e66855.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jairath NK, Dal Pra A, Vince R Jr., Dess RT, Jackson WC, Tosoian JJ, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021;79:374–83.

Article  CAS  PubMed  Google Scholar 

Morgan TM, Okoth LA, Spratt DE, Dunn R, Feng FY, Johnson AM, et al. Prospective randomized trial of gene expression classifier utility following radical prostatectomy (G-MINOR). J Clin Oncol. 2021;39:15–15.

Article  Google Scholar 

Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331–40.

Article  CAS  PubMed  Google Scholar 

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341–52.

Article  CAS  PubMed  Google Scholar 

Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413–21.

Article  CAS  PubMed  Google Scholar 

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Mohamad O, et al. Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2023;41:2428–35.

Article  CAS  PubMed  PubMed Central  Google Scholar